You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

54 search results for: expert insights

The Role of Type 2 Inflammation in Moderate-to-Severe AD
expert video

The Role of Type 2 Inflammation in Moderate-to-Severe AD

Dermatology
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to the systemic inflammation seen in patients with moderate-to-severe AD.
View more
Early Intervention and the Potential For Disease Modification in AD
expert video

Early Intervention and the Potential For Disease Modification in AD

Dermatology
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson discusses key considerations for disease modification and the importance of early intervention in treating patients with AD.
View more
Emerging Real-World Data on Advanced Systemic Therapies in AD
expert video

Emerging Real-World Data on Advanced Systemic Therapies in AD

Dermatology
In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Marjolein de-Bruin Weller highlights findings from the latest real-world studies on the use of advanced systemic treatments in patients with AD.
View more
Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Dermatology
Highlights from the ESPD 2023 ADVENT symposium: Exploring burden and comorbidities associated with moderate-to-severe atopic dermatitis in children.
View more
Can Early Intervention Shape the Course of Atopic Dermatitis?
expert video

Can Early Intervention Shape the Course of Atopic Dermatitis?

Dermatology
Dr. Paller presents highlights from recent clinical studies in AD, which highlight the potential benefits of early and effective AD treatment in modifying disease progression and mitigating atopic comorbidities.
View more
Factors Associated With Development of Atopic Comorbidities in AD
expert video

Factors Associated With Development of Atopic Comorbidities in AD

Dermatology
Dr. Paller discusses factors influencing AD chronicity and comorbidities, focusing on disease severity, early onset, heredity, multiple allergies, and urban living as important in evaluating AD’s lasting effects on children.
View more
Most Children With Atopic Dermatitis Have Uncontrolled Disease
expert video

Most Children With Atopic Dermatitis Have Uncontrolled Disease

Dermatology
Examine evidence from PEDI-BURDEN for the risk of flares in children with moderate-to-severe atopic dermatitis – a short soundbite from EADV 2022.
View more
The Risks of Associated Systemic and Atopic Comorbidities with AD
expert video

The Risks of Associated Systemic and Atopic Comorbidities with AD

Dermatology
Dr. Paller explores the multifaceted impact of AD, highlighting its association with various comorbidities such as food allergies, asthma, allergic rhinitis, and mental health disorders.
View more
Association of Younger Age of Onset With Persistence of AD
expert video

Association of Younger Age of Onset With Persistence of AD

Dermatology
Dr. Paller presents the Pediatric Eczema Elective Registry (PEER) findings, which suggest early-onset of AD is associated with higher risk of persistence of disease.
View more
The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis
expert video

The Role of Biomarkers in Clinical Decision-Making in Atopic Dermatitis

Dermatology
Dr. Stephan Weidinger talks about the role of biomarkers and their impact on clinical decision-making.
View more
Current systemic therapies have been shown to induce remission in a subset of AD patients
expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

Dermatology
Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IndiaChange country/region